Get high multiplex performance in an American-made product. Excellent sensitivity with CDC-recommended primers. All enzymes are synthesized in the United States. Fast turn-around times for customization that fits your workflow and format.

Detect SARS-CoV-2, Influenza A and Influenza B
in Less Than One Hour

Single-Tube RT-qPCR Detection

Made in America
Research Use Only

Direct: Heat 100ul VTM 95C for 5’
Indirect: CDC Recommended Protocol

CDC recommended targets and sequences

5-10 copies per reaction using CDC RNA extraction protocol, 10 copies per reaction using direct protocol.
Influenza A/B
25 copies per reaction using Direct Protocol

40 cycles using default ramp rates
Total cycling time appx 1’10”

  1. RT Incubation 50C 15’
  2. Enzyme Activation 95C 2’
  3. Amplification: 40 cycles (95C 3s, 60C 30s)

AzureSeq Plus

Multiplex Detection of
SARS-CoV-2, Influenza A and Influenza B

This multiplex RT-qPCR assay detects SARS-CoV-2, Influenza A and Influenza B on three different channels, determining if the sample contains one, two, or all three of the viruses. The assay uses RNase P as the sample control gene on the fourth channel.

Two Protocols – Same Kit

Direct: No RNA Extraction (LDT), straight from VTM/UTM*

Extracted: Use CDC Recommended RNA Extraction

N1 SARS-CoV-2, M1
Influenza A, NS2
Influenza B and human
RNaseP genes

5 ul approved VTM/UTM*
100 ng to 1 pg
extracted RNA (5ul)

M1 FluA = Quasar 670
NS2 FluB = HEX
RNaseP = TexasRed

Amplification 40 cycles,
LoD 5-10 copies

*Approved VTM/UTM: Copan, Puritan, CDC, Saline, PBS, MAWI EL


Contrived Clinical Samples

LoD study for AzureSeq Plus, Direct Protocol

The inactivated virus was spiked into a negative swab sample plus saline, at 10 copies/uL, 5 copies/uL, and 2.5 copies/uL. Samples were heated at 95C for 5’, then 5uL of sample was added to a final reaction (total 20uL) containing AzureSeq Plus reagents. 20 replicates of each concentration was amplified using recommended cycling conditions (see below). The LOD for the Direct Method (no RNA purification) has been determined to be 10 copies/uL for N1 SARS-CoV-2, M1 Influenza A, and NS2 Influenza B on the BioRad CFX96 Touch Real-time Detection System at least 95% of the time using the AzureSeq Direct Plus RT-qPCR Respiratory Infection Kit with recommended cycling conditions.

CoV-116.08SARS-CoV-2 Detected
CoV-223.2925.15SARS-CoV-2 Detected
CoV-324.9626.51SARS-CoV-2 Detected
CoV-429.9326.32SARS-CoV-2 Detected
CoV-527.5430.66SARS-CoV-2 Detected
CoV-630.1228.95SARS-CoV-2 Detected
CoV-730.0725.31SARS-CoV-2 Detected
CoV-822.8227.28SARS-CoV-2 Detected
CoV-926.2627.73SARS-CoV-2 Detected
CoV-1022.9126.26SARS-CoV-2 Detected
CoV-1116.12SARS-CoV-2 Detected
CoV-1225.1927.08SARS-CoV-2 Detected
CoV-1329.7927.66SARS-CoV-2 Detected
CoV-1421.01SARS-CoV-2 Detected
CoV-1520.1928.65SARS-CoV-2 Detected
CoV-1620.12SARS-CoV-2 Detected
CoV-1718.16SARS-CoV-2 Detected
CoV-1830.2625.12SARS-CoV-2 Detected
CoV-1926.9928.13SARS-CoV-2 Detected
CoV-2021.9331.44SARS-CoV-2 Detected
CoV-2121.36SARS-CoV-2 Detected
CoV-2223.2635.61SARS-CoV-2 Detected
CoV-2338.4127.43SARS-CoV-2 Detected
CoV-2425.6527.31SARS-CoV-2 Detected
CoV-2530.526.69SARS-CoV-2 Detected
CoV-2623.8643.88SARS-CoV-2 Detected
CoV-2719.7827.3SARS-CoV-2 Detected
CoV-2818.8130.02SARS-CoV-2 Detected
CoV-2930.2230.07SARS-CoV-2 Detected
CoV-3025.4628.73SARS-CoV-2 Detected
CoV-3129.1928.26SARS-CoV-2 Detected


SARS-CoV-2 Detection of Clinical Samples using AzureSeq Plus, Direct Protocol

FluB-126.5528.23Influenza B Detected
FluB-229.1928.99Influenza B Detected
FluB-33732.78Influenza B Detected
FluB-42729.53Influenza B Detected
FluB-513.6924Influenza B Detected
FluB-623.0322.33Influenza B Detected
FluB-720.3721.45Influenza B Detected
FluB-823.4822.13Influenza B Detected
FluB-920.0521.46Influenza B Detected
FluB-1021.1622.23Influenza B Detected
FluB-1122.8124.07Influenza B Detected
FluB-1221.8823.63Influenza B Detected
FluB-1326.3722.8Influenza B Detected
FluB-1419.4721.37Influenza B Detected
FluB-1520.2122.72Influenza B Detected
FluB-1621.5924.83Influenza B Detected
FluB-1720.522.71Influenza B Detected
FluB-1817.721.68Influenza B Detected
FluB-1921.5323.08Influenza B Detected
FluB-2020.6923.16Influenza B Detected
FluB-2117.9623.92Influenza B Detected
FluB-2224.1426.46Influenza B Detected
FluB-2322.4624.64Influenza B Detected
FluB-2422.8921.29Influenza B Detected
FluB-2520.0524.29Influenza B Detected
FluB-2621.8127.19Influenza B Detected


Influenza B detection of clinical samples using AzureSeq Plus, Direct Protocol

FluA-126.2228.97Influenza A Detected
FluA-224.7221.98Influenza A Detected
FluA-321.1435.33Influenza A Detected
FluA-424.3731.53Influenza A Detected
FluA-522.3123.42Influenza A Detected
FluA-625.93Not Detected
FluA-724.0424.57Influenza A Detected
FluA-822.3131.24Influenza A Detected
FluA-921.1328.81Influenza A Detected
FluA-1021.5522.14Influenza A Detected
FluA-1122.9423.6Influenza A Detected
FluA-1223.4119.36Influenza A Detected
FluA-1322.0527.76Influenza A Detected
FluA-1422.3529.78Influenza A Detected
FluA-1522.2434.06Influenza A Detected
FluA-1722.6525.1Influenza A Detected
FluA-1822.5624.96Influenza A Detected
FluA-1924.3824.54Influenza A Detected
FluA-2020.5222.08Influenza A Detected
FluA-2123.49Not Detected
FluA-2222.8221.73Influenza A Detected
FluA-2323.37Not Detected
FluA-2425.53Not Detected
FluA-2522.0529.16Influenza A Detected
FluA-2624.9921.6Influenza A Detected
FluA-2726.1825.01Influenza A Detected
FluA-2821.2227.84Influenza A Detected
FluA-2923.130.43Influenza A Detected
FluA-3022.7623.63Influenza A Detected
FluA-3122.9325.18Influenza A Detected
FluA-3221.3522.88Influenza A Detected


Influenza A detection of clinical samples using AzureSeq Plus, Direct Protocol

There was 100% correlation of the AzureSeq Plus RT-qPCR Respiratory Infection Kit to samples previously tested positive by Luminex MAGPix NxTag, Hologic Panther/ Fusion Flu A/B/RSV PCR for Influenza B and 87.5% for Influenza A. There was also 100% correlation to Zymo Quick SARS-CoV-2 kit for SARS-CoV-2 detection.

Target20 copies/µL10 copies/µL5 copies/µL1 copy/µL
Ct Average33.9535.1136.5639.47
Influenza APositive/Total20/2020/2020/200/0
Ct Average34.2235.5937.12n/a
Influenza BPositive/Total20/2020/2016/200/0
Ct Average33.0134.4336.58n/a

AzureSeq Plus Extracted Protocol LoD

CoV-117.5525.16SARS-CoV-2 Detected
CoV-223.4825.68SARS-CoV-2 Detected
CoV-317.8427.21SARS-CoV-2 Detected
CoV-423.3626.78SARS-CoV-2 Detected
CoV-518.0523.35SARS-CoV-2 Detected
CoV-629.6528.38SARS-CoV-2 Detected
CoV-721.7228.14SARS-CoV-2 Detected
CoV-825.4326.06SARS-CoV-2 Detected
CoV-919.7725.7SARS-CoV-2 Detected
CoV-1020.4725.16SARS-CoV-2 Detected
CoV-1126.8928.08SARS-CoV-2 Detected
CoV-1222.0627.18SARS-CoV-2 Detected
CoV-1327.0629.51SARS-CoV-2 Detected
CoV-1421.3625.14SARS-CoV-2 Detected
CoV-1526.5427.63SARS-CoV-2 Detected
CoV-1621.4625.88SARS-CoV-2 Detected
CoV-1723.0927.46SARS-CoV-2 Detected
CoV-1827.6926.28SARS-CoV-2 Detected
CoV-1929.824.83SARS-CoV-2 Detected
CoV-2022.7923.19SARS-CoV-2 Detected
CoV-2118.8123.96SARS-CoV-2 Detected
CoV-2219.4625.6SARS-CoV-2 Detected
CoV-2318.7123.74SARS-CoV-2 Detected
CoV-2420.1625.78SARS-CoV-2 Detected
CoV-2521.9527.33SARS-CoV-2 Detected
CoV-2625.6728.56SARS-CoV-2 Detected
CoV-2739.2127.35SARS-CoV-2 Detected
CoV-2829.1126.08SARS-CoV-2 Detected
CoV-2921.3126.08SARS-CoV-2 Detected
CoV-3018.8324.97SARS-CoV-2 Detected
CoV-3124.3528SARS-CoV-2 Detected


Clinical samples AzureSeq Plus Extracted SARS-CoV-2 Results

FluA-123.6730.57Influenza A Detected
FluA-221.1922.64Influenza A Detected
FluA-321.9224.05Influenza A Detected
FluA-420.8221.23Influenza A Detected
FluA-521.2123.08Influenza A Detected
FluA-627.0231.37Influenza A Detected
FluA-722.3929.15Influenza A Detected
FluA-820.5123.34Influenza A Detected
FluA-923.2529.49Influenza A Detected
FluA-1023.0121.77Influenza A Detected
FluA-1125.6231.64Influenza A Detected
FluA-1225.0220.6Influenza A Detected
FluA-1324.3325.37Influenza A Detected
FluA-1427.4824.97Influenza A Detected
FluA-1521.921.86Influenza A Detected
FluA-1622.8226.79Influenza A Detected
FluA-1724.6625.44Influenza A Detected
FluA-1822.0527.2Influenza A Detected
FluA-1922.8525.07Influenza A Detected
FluA-2024.4634.89Influenza A Detected
FluA-2121.1123.98Influenza A Detected
FluA-2224.0125.49Influenza A Detected
FluA-2323.8624.3Influenza A Detected
FluA-2420.3822.06Influenza A Detected
FluA-2521.9733.04Influenza A Detected
FluA-2624.9834.11Influenza A Detected
FluA-2722.2223.9Influenza A Detected
FluA-2821.523.28Influenza A Detected
FluA-2921.231.74Influenza A Detected
FluA-3021.9226.34Influenza A Detected
FluA-3122.7619.34Influenza A Detected
FluA-3225.4420.83Influenza A Detected


Clinical samples AzureSeq Plus Influenza A Results

Sample N1N1FluBRNasePFluAResult
FluB-119.7825.2Influenza B Detected
FluB-223.9125.87Influenza B Detected
FluB-330.2229.17Influenza B Detected
FluB-419.3524.69Influenza B Detected
FluB-521.8922.32Influenza B Detected
FluB-622.8521.82Influenza B Detected
FluB-720.6319.17Influenza B Detected
FluB-823.7220.08Influenza B Detected
FluB-917.919.66Influenza B Detected
FluB-1019.2920.02Influenza B Detected
FluB-1122.8722.09Influenza B Detected
FluB-1224.3921.62Influenza B Detected
FluB-1325.7220.44Influenza B Detected
FluB-1417.9719.01Influenza B Detected
FluB-1518.8720.47Influenza B Detected
FluB-1620.9224.52Influenza B Detected
FluB-1719.3420.59Influenza B Detected
FluB-1817.2521.34Influenza B Detected
FluB-192020.19Influenza B Detected
FluB-2019.0720.82Influenza B Detected
FluB-2116.6520.95Influenza B Detected
FluB-2221.9825.23Influenza B Detected
FluB-2320.6122.96Influenza B Detected
FluB-2422.0619.06Influenza B Detected
FluB-2518.722.98Influenza B Detected
FluB-2619.3426.43Influenza B Detected


Clinical samples AzureSeq Plus Influenza B Results

There was 100% correlation of the AzureSeq Plus RT-qPCR Respiratory Infection Kit to samples previously tested positive by Luminex MAGPix NxTag, Hologic Panther/ Fusion Flu A/B/RSV PCR for Influenza A and Influenza B. There was also 100% correlation to Zymo Quick SARS-CoV-2 kit for SARS-CoV-2 detection.


SKU# 20 ul Reactions Content
AzureSeq Plus 4-200 200 In Solution: InhibiTaq Plus, Hot Start Mastermix, RTScript, SARS CoV-2 and RNaseP primers and probes, DTT, UDG, RNase Inhibitor
AzureSeq Plus 4-1000 1000
AzureSeq Direct-2000 2000

For Research Use Only. CLIA labs must file an LDT or EUA.

Contact Us for More Information

Suggested CPT Code: 87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.

Depending on your cycler, approximately 70′-75′.

For N1, FAM (absorption 493nm, emission 517nm)

For N2, HEX (absorption 533nm, emission 559nm)

For RnaseP, ROX/Tx Red (absorption 583nm, emission 603nm)

Yes. Our FDA Facility Registration number is 10076042

Yes, we can make AzureSeq in tube and 96/384-well format.

  • We anticipate mid-August 2020. Samples are available now for testing.
  • Will you submit for EUA? Yes, assuming validation data is comparable or superior to the wet version. It is currently RUO- Not For Diagnostic Use.

As of Jul 12, 2020 we can provide 2M reactions/week. This can be further scaled with 10 days notice. Please contact us for the most up-to-date information.

Both are available.

Omega Total RNA Spin Columns and KingFisher MagMax

For validation N1=5 copies/rxn, N2=10 copies/rxn.

1000 cp/ul RNaseP, 200 cp/ul of N


N1, N2 capsid and RP-P

It was validated using standard qPCR instruments including: QuantStudio series, BioRad FX.

It is EUA-Validated, not EUA-Authorized. At this time, CLIA users may choose to submit their own EUA. Upon request, we will send the FDA EUA Submission for AzureSeq.

Suggested CPT Code: 87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique

Product Disclaimer

Category 1 CPT Code for AzureSeq Plus

87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique

Download SDS Sheets


By highlighting threatened or endangered species, SeqOnce hopes to draw attention to conservation efforts. As biologists, we believe humanity is better served when ecologies are maintained and there is diversity of life.

SeqOnce supports protecting and conserving endangered and threatened species.

Learn More Here


Go to Top